Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identifying risk factors for predominant negative symptoms from early stages in schizophrenia: A longitudinal and sex-specific study in first-episode schizophrenia patients.
Mezquida G, Amoretti S, Bioque M, García-Rizo C, Sánchez-Torres AM, Pina-Camacho L, Lopez-Pena P, Mané A, Rodriguez-Jimenez R, Corripio I, Sarró S, Ibañez A, Usall J, García-Portilla MP, Vieta E, Mas S, Cuesta MJ, Parellada M, González-Pinto A, Berrocoso E, Bernardo M; 2EPs Group. Mezquida G, et al. Among authors: usall j. Span J Psychiatry Ment Health. 2023 Jul-Sep;16(3):159-168. doi: 10.1016/j.rpsm.2023.01.004. Epub 2023 Feb 1. Span J Psychiatry Ment Health. 2023. PMID: 37716849
Gender differences in outcomes of acute mania: a 12-month follow-up study.
Miquel L, Usall J, Reed C, Bertsch J, Vieta E, González-Pinto A, Angst J, Nolen W, van Rossum I, Haro JM. Miquel L, et al. Among authors: usall j. Arch Womens Ment Health. 2011 Apr;14(2):107-13. doi: 10.1007/s00737-010-0185-z. Epub 2010 Oct 19. Arch Womens Ment Health. 2011. PMID: 20957398
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R; Abordaje Síntomas Negativos Esquizofrenia Group. Usall J, et al. J Clin Psychiatry. 2014 Jun;75(6):608-15. doi: 10.4088/JCP.13m08551. J Clin Psychiatry. 2014. PMID: 25004184 Clinical Trial.
Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study.
Cuesta MJ, Sánchez-Torres AM, Cabrera B, Bioque M, Merchán-Naranjo J, Corripio I, González-Pinto A, Lobo A, Bombín I, de la Serna E, Sanjuan J, Parellada M, Saiz-Ruiz J, Bernardo M; PEPs Group. Cuesta MJ, et al. Schizophr Res. 2015 May;164(1-3):65-73. doi: 10.1016/j.schres.2015.02.022. Epub 2015 Mar 26. Schizophr Res. 2015. PMID: 25819935
The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study.
Mezquida G, Cabrera B, Bioque M, Amoretti S, Lobo A, González-Pinto A, Espliego A, Corripio I, Vieta E, Castro-Fornieles J, Bergé D, Escartí MJ, Ibañez Á, Penadés R, Sánchez-Torres AM, Bernardo M; PEPs Group. Mezquida G, et al. Schizophr Res. 2017 Nov;189:84-90. doi: 10.1016/j.schres.2017.01.047. Epub 2017 Feb 6. Schizophr Res. 2017. PMID: 28185786
Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.
Mas S, Gassó P, Torra M, Bioque M, Lobo A, González-Pinto A, Olmeda MS, Corripio I, Vieta E, Castro-Fornieles J, Rodriguez-Jimenez R, Bobes J, Usall J, Llerena A, Saiz-Ruiz J, Bernardo M, Lafuente A, PEPs Group. Mas S, et al. Among authors: usall j. Eur Neuropsychopharmacol. 2017 Jul;27(7):647-656. doi: 10.1016/j.euroneuro.2017.03.012. Epub 2017 Apr 5. Eur Neuropsychopharmacol. 2017. PMID: 28389049
Persistent Negative Symptoms in First-Episode Psychosis: Early Cognitive and Social Functioning Correlates and Differences Between Early and Adult Onset.
Puig O, Baeza I, de la Serna E, Cabrera B, Mezquida G, Bioque M, Lobo A, González-Pinto A, Parellada M, Corripio I, Vieta E, Bobes J, Usall J, Contreras F, Cuesta MJ, Bernardo M, Castro-Fornieles J; PEPs Group. Puig O, et al. Among authors: usall j. J Clin Psychiatry. 2017 Nov/Dec;78(9):1414-1422. doi: 10.4088/JCP.16m11122. J Clin Psychiatry. 2017. PMID: 28922588
m-RESIST, a complete m-Health solution for patients with treatmentresistant schizophrenia: a qualitative study of user needs and acceptability in the Barcelona metropolitan area.
Huerta-Ramos E, Marcó-García S, Escobar-Villegas MS, Rubio-Abadal E, Ochoa S, Grasa Bello EM, Alonso Solís A, Rabella M, Berdun J, Hospedales M, M-Resist G, Corripio I, Usall J. Huerta-Ramos E, et al. Among authors: usall j. Actas Esp Psiquiatr. 2017 Nov;45(6):277-89. Epub 2017 Nov 1. Actas Esp Psiquiatr. 2017. PMID: 29199762 Free article.
Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?
Ballesteros A, Sánchez-Torres AM, López-Ilundain JM, Cabrera B, Lobo A, González-Pinto AM, Díaz-Caneja C, Corripio I, Vieta E, de la Serna E, Bobes J, Usall J, Contreras F, Lorente-Omeñaca R, Mezquida G, Bernardo M, Cuesta MJ; PEPs Group. Ballesteros A, et al. Among authors: usall j. Psychol Med. 2018 Oct;48(13):2247-2256. doi: 10.1017/S0033291717003774. Epub 2018 Jan 14. Psychol Med. 2018. PMID: 29331153
Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis.
Soria V, González-Rodríguez A, Huerta-Ramos E, Usall J, Cobo J, Bioque M, Barbero JD, García-Rizo C, Tost M, Monreal JA; PNECAT Group; Labad J. Soria V, et al. Among authors: usall j. Psychoneuroendocrinology. 2018 Jul;93:8-19. doi: 10.1016/j.psyneuen.2018.04.012. Epub 2018 Apr 14. Psychoneuroendocrinology. 2018. PMID: 29680774
259 results